Cargando…
Safety Evaluation of Recombinant Fusion Protein RP22 as a Skin Test Reagent for Tuberculosis Diagnosis: A Phase I Clinical Trial
INTRODUCTION: This phase I clinical trial was conducted to evaluate the safety of RP22 as a skin test reagent for tuberculosis (TB) diagnosis and to explore the appropriate dosage. METHODS: We used a randomized, double-blind, placebo-controlled identification allergen (IA) skin test. A total of 72 h...
Autores principales: | Xia, Lu, Liu, Xu-hui, Zhao, Zhang-yan, Li, Tao, Xi, Xiu-hong, Liu, Ping, Huang, Wei, Fan, Xiao-yong, Wu, Xue-qiong, Lu, Shui-hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8116472/ https://www.ncbi.nlm.nih.gov/pubmed/33829391 http://dx.doi.org/10.1007/s40121-021-00435-5 |
Ejemplares similares
-
Utility of recombinant fusion protein ESAT6-CFP10 skin test for differential diagnosis of active tuberculosis: A prospective study
por: Yuan, Yuan, et al.
Publicado: (2023) -
Nanobody‑horseradish peroxidase and -EGFP fusions as reagents to detect porcine parvovirus in the immunoassays
por: Lu, Qizhong, et al.
Publicado: (2020) -
Validation of Recombinant Heparan Sulphate Reagents for CNS Repair
por: Lindsay, Susan L., et al.
Publicado: (2023) -
Sustainable and practical formation of carbon–carbon and carbon–heteroatom bonds employing organo-alkali metal reagents
por: Huo, Lu-Qiong, et al.
Publicado: (2022) -
Preclinical study and phase I clinical safety evaluation of recombinant Mycobacterium tuberculosis ESAT6 protein
por: Du, Wei-Xin, et al.
Publicado: (2013)